Jazz Pharmaceuticals

JAZZ on Nasdaq. Jazz Pharmaceuticals sells medicines for rare diseases to patients and doctors. Market value $15.5bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Recent profit includes a big one-time charge, so we price the company excluding that charge.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
10.7%very high

For every $100 of what the whole company costs, it produced $10.69 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026, without the one-off
14.9×fair

You pay 14.9 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
1.4%five-year median

Each dollar kept in the business earns 1 cents a year. Above 10 is good.

Quality score: 66 of 100. Price score: 92 of 100. Our list needs 70 on quality and 60 on price.

$236.45 a share, 51% above its 1-year low

Over the past year the price has ranged from $156.95 to $266.38.

Pays no dividend

Price from Thursday’s close (19 November).

Five years of cash, in billions

0.8
1.2
1.1
1.4
1.3
1.6
2021202220232024202512 monthsto Sep '26
Revenue
$3.1bn$3.7bn$3.8bn$4.1bn$4.3bn
Operating margin
5.5%-1.8%15.1%17.6%-10.1%
Debt to equity
1.531.861.531.491.24
Shares outstanding
0.06bn0.06bn0.06bn0.06bn0.06bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 8 checks we could run
  • Profit backed by cash (accruals)No
  • Debt1.24× equity
  • Revenue growth, five yearsStrong, 12.5% a year
  • Buying back its own sharesRoughly flat

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.2 billion last quarter, up 10% on a year ago.
  • A loss of $483 million, after a profit of $251 million a year ago.
  • It keeps 9 cents of each $1 of sales as operating profit, after losing 12 cents a year earlier.
  • Spare cash over the past 12 months: $1.6 billion, up from $1.3 billion.
  • 5% more shares than a year ago. Each share owns a bit less of the company.
  • Debt is $3.5 billion more than cash, down from $4 billion a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$1.1bn
March 2025$898m
June 2025$1.0bn
September 2025$1.1bn
December 2025$1.2bn
March 2026$1.1bn
June 2026$1.2bn
September 2026$1.2bn
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024$191m
March 2025-$93m
June 2025-$719m
September 2025$251m
December 2025$203m
March 2026$293m
June 2026$193m
September 2026-$483m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
24 February 2026
Next quarterly (estimated, 10-Q)
1 February 2027

Who owns it

7 long-term investors we follow own it, up from 6 last quarter. 643 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

2 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 11 sold $81m, $34m of it under preset trading plans.

  • COZADD BRUCE C
    Director
    Sold
    Date
    6 November 2026
    Shares
    68,808
    Price
    $235.95
    Value
    $16m
  • Carr Patricia
    SVP, Chief Accounting Officer
    Sold
    Date
    4 November 2026
    Shares
    1,413
    Price
    $231.36
    Value
    $326,910
  • GALA RENEE D
    President & CEO, Director
    Sold
    under a preset trading plan
    Date
    3 November 2026
    Shares
    1,000
    Price
    $225.37
    Value
    $225,370
  • COZADD BRUCE C
    Director
    Sold
    under a preset trading plan
    Date
    2 November 2026
    Shares
    6,000
    Price
    $215.84
    Value
    $1m
  • GALA RENEE D
    President & CEO, Director
    Sold
    under a preset trading plan
    Date
    6 October 2026
    Shares
    2,000
    Price
    $236.40
    Value
    $472,800
  • COZADD BRUCE C
    Director
    Sold
    under a preset trading plan
    Date
    1 October 2026
    Shares
    6,000
    Price
    $230.33
    Value
    $1m
  • Patil Neena M
    EVP & Chief Legal Officer
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    1,200
    Price
    $240.94
    Value
    $289,128
  • GALA RENEE D
    President & CEO
    Sold
    under a preset trading plan
    Date
    8 September 2026
    Shares
    2,000
    Price
    $243.03
    Value
    $486,060
  • COZADD BRUCE C
    Director
    Sold
    under a preset trading plan
    Date
    1 September 2026
    Shares
    6,000
    Price
    $250.13
    Value
    $2m
  • Iannone Robert
    EVP, Global Head of R&D & CMO
    Sold
    under a preset trading plan
    Date
    27 August 2026
    Shares
    76,921
    Price
    $249.70
    Value
    $19m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Feb 2026, plus the 10-Q filed 2 Nov 2026 and 13 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.